SOST and osteoporosis: In a phase III clinical trial, the subcutaneous administration of antibodies to sclerostin (such as romosozumab, a monoclonal antibody that binds sclerostin) demonstrated efficacy in enhancing BMD compared to the placebo in postmenopausal women with osteoporosis and men with osteoporosis (84, 88).